Document is current
Any future updates will be listed below
-
Authors
Mozaffari Jovein, Miriam https://orcid.org/0009-0001-5304-8943
Ihorst, Gabriele https://orcid.org/0000-0002-8091-1589
Duque-Afonso, Jesús https://orcid.org/0000-0002-8287-5673
Wäsch, Ralph https://orcid.org/0000-0002-0813-3444
Bertz, Hartmut
Wehr, Claudia
Duyster, Justus
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Finke, Jürgen https://orcid.org/0000-0002-1799-5927
Scherer, Florian https://orcid.org/0000-0001-9635-5487
- License Information
-
More Information
Article History
Received: 1 October 2023
Revised: 16 November 2023
Accepted: 20 November 2023
First Online: 10 December 2023
Competing interests
: MMJ declares no competing interests. FS receives research funding from Roche Sequencing Solutions, Gilead, and Takeda, and receives honoraria from AstraZeneca. JF declares no competing interests. GI declares no competing interests. JD-A received speakers honoraria from Roche, Amgen, Riemser, SOBI, IPSEN, NovoNordisk and AstraZeneca and travel support from Lilly, Roche, Gilead and SOBI. JD declares no competing interests. CW received honoraria from Takeda. HB declares no competing interests. RW received honoraria from Abbvie, Amgen, BMS/Celgene, Janssen, Kite/Gilead, Novartis, Pfizer and Sanofi. RZ received honoraria from Incyte, Novartis, Sanofi and Mallinckrodt all outside of the work reported here.
